Evidence map›Paper›PMID 24455267›Full record

ArticleMultiple sclerosis international2013

Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries.

Mohammed Aljumah, Raed Alroughani, I Alsharoqi, Saeed A Bohlega, Maurice Dahdaleh, Dirk Deleu, Khaled Esmat, Ahmad Khalifa, Mohammad A Sahraian, Miklós Szólics and 4 more

Abstract read
In one paragraph

Article in Multiple sclerosis international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mohammed AljumahKing Abdullah International Medical Research Center, King Saud Ben Abdulaziz University for Health Sciences, National Guard Health Affairs, P.O. Box 22490, Riyadh 11426, Saudi Arabia ; Prince Mohammed Ben Abdulaziz Hospital, Ministry of Health, Riyadh 1176, Saudi Arabia.
Raed AlroughaniDivision of Neurology, Amiri Hospital Kuwait, P.O. Box 1661, 73767 Qurtoba, Kuwait ; Division of Neurology, Dasman Diabetes Institute, 15462 Dasman, Kuwait.
I AlsharoqiClinical Neurosciences Department, Salmaniya Medical Complex, 20525 Manama, Bahrain.
Saeed A BohlegaDepartment of Neurosciences, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Maurice DahdalehDepartment of Internal Medicine, Neurology Section, Arab Medical Center and Khalidi Hospital, P.O. Box 925209, Amman 11190, Jordan.
Dirk DeleuDepartment of Neurology (Medicine), Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
Khaled EsmatMerck Serono Intercontinental Region, Dubai 22730, UAE.
Ahmad KhalifaDepartment of Neurology, Damascus Hospital, P.O. Box 10053, Damascus, Syria.
Mohammad A SahraianMS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran 1136746911, Iran.
Miklós SzólicsDivision of Neurology, Department of Medicine, Tawam Hospital, P.O. Box 15258, Al Ain, UAE.
Abdulrahman AltahanNeurology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh 11691, Saudi Arabia.
Bassem I YamoutAmerican University of Beirut Medical Center, Multiple Sclerosis Center, P.O. Box 11-0236, Beirut, Lebanon.
Peter RieckmannNeurologische Klinik Bamberg, 96049 Bamberg, Germany.
Abdulkader DaifNeurology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh 11691, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of multiple sclerosis (MS) is now considered to be medium-to-high in the Middle East and is rising, particularly among women. While the characteristics of the disease and the response of patients to disease-modifying therapies are generally comparable between the Middle East and other areas, significant barriers to achieving optimal care for MS exist in these developing nations. A group of physicians involved in the management of MS in ten Middle Eastern countries met to consider the future of MS care in the region, using a structured process to reach a consensus. Six key priorities were identified: early diagnosis and management of MS, the provision of multidisciplinary MS centres, patient engagement and better communication with stakeholders, regulatory body education and reimbursement, a commitment to research, and more therapy options with better benefit-to-risk ratios. The experts distilled these priorities into a single vision statement: "Optimization of patient-centred multidisciplinary strategies to improve the quality of life of people with MS." These core principles will contribute to the development of a broader consensus on the future of care for MS in the Middle East.

Identifiers

PMID24455267
PMCPMC3877627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.